#METABOLOMICS WORKBENCH Mamo_O_20250120_171530 DATATRACK_ID:5547 STUDY_ID:ST003722 ANALYSIS_ID:AN006641 PROJECT_ID:PR002311
VERSION             	1
CREATED_ON             	July 6, 2025, 8:13 pm
#PROJECT
PR:PROJECT_TITLE                 	Metabolomic changes in plasma during immobilization and FoxO1 overexpression in
PR:PROJECT_TITLE                 	mice.
PR:PROJECT_SUMMARY               	To better understand the metabolic changes in plasma during immobilization and
PR:PROJECT_SUMMARY               	FoxO1 overexpression, we performed a metabolomic analysis of plasma from
PR:PROJECT_SUMMARY               	11-week-old C57BL/6J male mice immobilized for 7 days and from age-matched
PR:PROJECT_SUMMARY               	FoxO1-Tg male mice and age-matched control male mice using CE-TOFMS.
PR:INSTITUTE                     	Kyoto Prefectural University
PR:LAST_NAME                     	Kamei
PR:FIRST_NAME                    	Yasutomi
PR:ADDRESS                       	1-5 Hangi-cho, Shimogamo, Sakyo-ku, Kyoto, Kyoto, 606-8522, Japan
PR:EMAIL                         	oyabu0507@gmail.com
PR:PHONE                         	+81-75-703-5661
#STUDY
ST:STUDY_TITLE                   	Metabolomic analysis of plasma from control, immobilized and FoxO1-Tg mice.
ST:STUDY_SUMMARY                 	The Forkhead box O (FoxO) transcription factors have been reported to be
ST:STUDY_SUMMARY                 	critical factors for muscle atrophy in a variety of pathological and
ST:STUDY_SUMMARY                 	physiological conditions, and genetically induced FoxO1 overexpression resulted
ST:STUDY_SUMMARY                 	in severe muscle atrophy. To better understand the metabolic changes in plasma
ST:STUDY_SUMMARY                 	during immobilization and FoxO1 overexpression, we performed a metabolomic
ST:STUDY_SUMMARY                 	analysis of plasma from 11-week-old C57BL/6J male mice immobilized for 7 days
ST:STUDY_SUMMARY                 	and from age-matched FoxO1-Tg male mice and age-matched control male mice using
ST:STUDY_SUMMARY                 	CE-TOFMS. Our data show that immobilized mice were characterized by a reduction
ST:STUDY_SUMMARY                 	of many metabolites, including 2-oxoglutaric acid (α-ketoglutarate: α-KG),
ST:STUDY_SUMMARY                 	2-hydroxyisobutyric acid, and guanidinosuccinic acid, in the plasma.
ST:INSTITUTE                     	Kyoto Prefectural University
ST:LAST_NAME                     	Kamei
ST:FIRST_NAME                    	Yasutomi
ST:ADDRESS                       	1-5 Hangi-cho, Shimogamo, Sakyo-ku, Kyoto, Kyoto, 606-8522, Japan
ST:EMAIL                         	oyabu0507@gmail.com
ST:PHONE                         	+81-75-703-5661
#SUBJECT
SU:SUBJECT_TYPE                  	Mammal
SU:SUBJECT_SPECIES               	Mus musculus
SU:TAXONOMY_ID                   	10090
SU:GENOTYPE_STRAIN               	C57BL/6J and FOXO1-Tg
SU:AGE_OR_AGE_RANGE              	11-week-old
SU:WEIGHT_OR_WEIGHT_RANGE        	24.7 g, 23.0 g, 24.8 g, and 22.5 g for control mice (n = 4) 18.2 g, 22.4 g, 20.3
SU:WEIGHT_OR_WEIGHT_RANGE        	g, and 20.0 g for FoxO1-Tg mice (n = 4), and 21.4 g, 21.3 g, 22.5 g, and 23.6 g
SU:WEIGHT_OR_WEIGHT_RANGE        	for immobilized mice (n = 4).
SU:GENDER                        	Male
SU:ANIMAL_ANIMAL_SUPPLIER        	CLEA Japan (Tokyo, Japan)
SU:ANIMAL_LIGHT_CYCLE            	12-h light-dark cycle
SU:ANIMAL_FEED                   	CE2
SU:SPECIES_GROUP                 	Mammals
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data
SUBJECT_SAMPLE_FACTORS           	P-C-1	C-1	Group:Control group | Sample source:Plasma | Genotype:wild-type | Treatment:Control | Time:-	RAW_FILE_NAME(raw data file name_anion)=TMDUM002_A_20100123_P-c-1_d5-2.mzML; RAW_FILE_NAME(raw data file name_cation)=TMDUM002_C_20100125_P-C-1_d1.mzML
SUBJECT_SAMPLE_FACTORS           	P-C-3	C-3	Group:Control group | Sample source:Plasma | Genotype:wild-type | Treatment:Control | Time:-	RAW_FILE_NAME(raw data file name_anion)=TMDUM002_A_20100123_P-c-3_d5.mzML; RAW_FILE_NAME(raw data file name_cation)=TMDUM002_C_20100125_P-C-3_d1.mzML
SUBJECT_SAMPLE_FACTORS           	P-C-4	C-4	Group:Control group | Sample source:Plasma | Genotype:wild-type | Treatment:Control | Time:-	RAW_FILE_NAME(raw data file name_anion)=TMDUM002_A_20100123_P-c-4_d5.mzML; RAW_FILE_NAME(raw data file name_cation)=TMDUM002_C_20100125_P-C-4_d1.mzML
SUBJECT_SAMPLE_FACTORS           	P-C-5	C-5	Group:Control group | Sample source:Plasma | Genotype:wild-type | Treatment:Control | Time:-	RAW_FILE_NAME(raw data file name_anion)=TMDUM002_A_20100123_P-c-5_d5.mzML; RAW_FILE_NAME(raw data file name_cation)=TMDUM002_C_20100125_P-C-5_d1.mzML
SUBJECT_SAMPLE_FACTORS           	P-Tg-1	Tg-1	Group:FOXO1-Tg group | Sample source:Plasma | Genotype:FOXO1-Tg | Treatment:Control | Time:-	RAW_FILE_NAME(raw data file name_anion)=TMDUM002_A_20100123_P-Tg-1_d5.mzML; RAW_FILE_NAME(raw data file name_cation)=TMDUM002_C_20100125_P-Tg-1_d1.mzML
SUBJECT_SAMPLE_FACTORS           	P-Tg-2	Tg-2	Group:FOXO1-Tg group | Sample source:Plasma | Genotype:FOXO1-Tg | Treatment:Control | Time:-	RAW_FILE_NAME(raw data file name_anion)=TMDUM002_A_20100123_P-Tg-2_d5.mzML; RAW_FILE_NAME(raw data file name_cation)=TMDUM002_C_20100125_P-Tg-2_d1.mzML
SUBJECT_SAMPLE_FACTORS           	P-Tg-3	Tg-3	Group:FOXO1-Tg group | Sample source:Plasma | Genotype:FOXO1-Tg | Treatment:Control | Time:-	RAW_FILE_NAME(raw data file name_anion)=TMDUM002_A_20100123_P-Tg-3_d5.mzML; RAW_FILE_NAME(raw data file name_cation)=TMDUM002_C_20100125_P-Tg-3_d1.mzML
SUBJECT_SAMPLE_FACTORS           	P-Tg-5	Tg-5	Group:FOXO1-Tg group | Sample source:Plasma | Genotype:FOXO1-Tg | Treatment:Control | Time:-	RAW_FILE_NAME(raw data file name_anion)=TMDUM002_A_20100123_P-Tg-5_d5.mzML; RAW_FILE_NAME(raw data file name_cation)=TMDUM002_C_20100125_P-Tg-5_d1.mzML
SUBJECT_SAMPLE_FACTORS           	P-P-4	P-4	Group:Plaster group | Sample source:Plasma | Genotype:wild-type | Treatment:immobilization | Time:7 days	RAW_FILE_NAME(raw data file name_anion)=TMDUM002_A_20100123_P-P-4_d5.mzML; RAW_FILE_NAME(raw data file name_cation)=TMDUM002_C_20100125_P-P-4_d1.mzML
SUBJECT_SAMPLE_FACTORS           	P-P-5	P-5	Group:Plaster group | Sample source:Plasma | Genotype:wild-type | Treatment:immobilization | Time:7 days	RAW_FILE_NAME(raw data file name_anion)=TMDUM002_A_20100123_P-P-5_d5.mzML; RAW_FILE_NAME(raw data file name_cation)=TMDUM002_C_20100125_P-P-5_d1.mzML
SUBJECT_SAMPLE_FACTORS           	P-P-7	P-7	Group:Plaster group | Sample source:Plasma | Genotype:wild-type | Treatment:immobilization | Time:7 days	RAW_FILE_NAME(raw data file name_anion)=TMDUM002_A_20100123_P-P-7_d5.mzML; RAW_FILE_NAME(raw data file name_cation)=TMDUM002_C_20100125_P-P-7_d1.mzML
SUBJECT_SAMPLE_FACTORS           	P-P-8	P-8	Group:Plaster group | Sample source:Plasma | Genotype:wild-type | Treatment:immobilization | Time:7 days	RAW_FILE_NAME(raw data file name_anion)=TMDUM002_A_20100123_P-P-8_d5.mzML; RAW_FILE_NAME(raw data file name_cation)=TMDUM002_C_20100125_P-P-8_d1.mzML
#COLLECTION
CO:COLLECTION_SUMMARY            	Blood from 11-week-old C57BL/6J male mice immobilized for 7 days, age-matched
CO:COLLECTION_SUMMARY            	FOXO1-Tg male mice, and age-matched control male mice was collected into
CO:COLLECTION_SUMMARY            	Venoject II vacuum blood collection tube (blood collection tube) and plasma was
CO:COLLECTION_SUMMARY            	separated by centrifugation at 800 × g for 5 min, rapidly frozen in liquid
CO:COLLECTION_SUMMARY            	nitrogen, and stored at -80°C (n = 4 mice/group).
CO:SAMPLE_TYPE                   	Blood (plasma)
CO:STORAGE_CONDITIONS            	-80℃
#TREATMENT
TR:TREATMENT_SUMMARY             	The right hindlimb of C57BL/6J male mice was immobilized (unloaded) with plaster
TR:TREATMENT_SUMMARY             	cast. This procedure prevented movement of the immobilized leg alone. Mice not
TR:TREATMENT_SUMMARY             	exposed to atrophic conditions were used as controls.
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	50 µL of plasma sample and 450 µL methanol solution (internal standard
SP:SAMPLEPREP_SUMMARY            	concentration: 10 μM) were added to each tube and stirred. To this, 500 μL
SP:SAMPLEPREP_SUMMARY            	chloroform and 200 μL Milli-Q water were added, stirred, and centrifuged (2,300
SP:SAMPLEPREP_SUMMARY            	× g, 4°C, 5 min). After centrifugation, 200 μL × 2 of the aqueous phases was
SP:SAMPLEPREP_SUMMARY            	transferred to ultrafiltration tubes (MILLIPORE, Ultrafree MC UFC3 LCC
SP:SAMPLEPREP_SUMMARY            	centrifugal filter unit 5 KDa). This was centrifuged (9,100 × g, 4°C, 120 min)
SP:SAMPLEPREP_SUMMARY            	and subjected to ultrafiltration. The filtrate was dried and redissolved in 25
SP:SAMPLEPREP_SUMMARY            	μL Milli-Q water for for metabolome analysis at Human Metabolome Technologies
SP:SAMPLEPREP_SUMMARY            	(HMT).
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_SUMMARY        	The column used has a model number TSP050375 from Polymicro Technologies.
CH:CHROMATOGRAPHY_SUMMARY        	Specifically, this item was purchased and then cut and processed for use.
CH:CHROMATOGRAPHY_TYPE           	CE
CH:INSTRUMENT_NAME               	Agilent 7100 CE
CH:COLUMN_NAME                   	Fused silica capillary i.d. 50 μm x 80 cm
CH:SOLVENT_A                     	Anion Buffer Solution (p/n : H3302-1021 for run buffer and p/n : H3302-1022 for
CH:SOLVENT_A                     	rinse buffer)
CH:SOLVENT_B                     	N/A
CH:FLOW_GRADIENT                 	N/A
CH:FLOW_RATE                     	N/A
CH:COLUMN_TEMPERATURE            	N/A
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:INSTRUMENT_NAME               	Agilent 6230 TOF
MS:INSTRUMENT_TYPE               	TOF
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	NEGATIVE
MS:MS_COMMENTS                   	CE-TOFMS(Basic) negative(Anion) mode Run buffer : Anion Buffer Solution ( p/n :
MS:MS_COMMENTS                   	H3302-1021) Rinse buffer : Anion Buffer Solution ( p/n : H3302-1022) Sample
MS:MS_COMMENTS                   	injection : Pressure injection 50 mbar, 25 sec CE voltage : Positive, 30 kV MS
MS:MS_COMMENTS                   	ionization : ESI Negative MS capillary voltage : 3,500 V MS scan range : m/z
MS:MS_COMMENTS                   	50-1,000 Sheath liquid : HMT Sheath Liquid ( p/n : H3301-1020)
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS	arbitrary unit
MS_METABOLITE_DATA_START
Samples	C-1	C-3	C-4	C-5	Tg-1	Tg-2	Tg-3	Tg-5	P-4	P-5	P-7	P-8
Factors	Group:Control group | Sample source:Plasma | Genotype:wild-type | Treatment:Control | Time:-	Group:Control group | Sample source:Plasma | Genotype:wild-type | Treatment:Control | Time:-	Group:Control group | Sample source:Plasma | Genotype:wild-type | Treatment:Control | Time:-	Group:Control group | Sample source:Plasma | Genotype:wild-type | Treatment:Control | Time:-	Group:FOXO1-Tg group | Sample source:Plasma | Genotype:FOXO1-Tg | Treatment:Control | Time:-	Group:FOXO1-Tg group | Sample source:Plasma | Genotype:FOXO1-Tg | Treatment:Control | Time:-	Group:FOXO1-Tg group | Sample source:Plasma | Genotype:FOXO1-Tg | Treatment:Control | Time:-	Group:FOXO1-Tg group | Sample source:Plasma | Genotype:FOXO1-Tg | Treatment:Control | Time:-	Group:Plaster group | Sample source:Plasma | Genotype:wild-type | Treatment:immobilization | Time:7 days	Group:Plaster group | Sample source:Plasma | Genotype:wild-type | Treatment:immobilization | Time:7 days	Group:Plaster group | Sample source:Plasma | Genotype:wild-type | Treatment:immobilization | Time:7 days	Group:Plaster group | Sample source:Plasma | Genotype:wild-type | Treatment:immobilization | Time:7 days
Glyoxylic acid	1.2E-02	2.4E-02	2.2E-02	2.9E-02	2.0E-02	2.1E-02	2.4E-02	1.9E-02	1.9E-02	2.2E-02	2.6E-02	2.0E-02
Propionic acid	3.5E-02	3.8E-02	3.8E-02	3.4E-02	3.3E-02	3.6E-02	3.3E-02	3.4E-02	4.1E-02	3.0E-02	3.1E-02	3.8E-02
Pyruvic acid	1.7E-01	2.6E-01	3.8E-01	2.0E-01	2.4E-01	3.7E-01	2.5E-01	1.9E-01	2.1E-01	2.1E-01	1.9E-01	6.0E-02
Butyric acid	6.6E-02	6.2E-02	4.4E-02	6.0E-02	2.8E-02	4.1E-02	5.3E-02	5.4E-02	3.9E-02	4.0E-02	6.4E-02	7.0E-02
Lactic acid	2.0E+01	2.3E+01	5.4E+01	1.8E+01	3.3E+01	3.4E+01	2.0E+01	1.7E+01	1.5E+01	1.6E+01	1.7E+01	5.9E+00
3-Methylbutanoic acid	5.6E-02	5.5E-02	4.5E-02	6.2E-02	1.9E-02	3.5E-02	4.8E-02	4.9E-02	4.3E-02	3.6E-02	6.5E-02	6.3E-02
2-Hydroxybutyric acid	5.1E-02	1.4E-01	1.4E-01	9.0E-02	1.1E-01	1.3E-01	1.6E-01	8.1E-02	1.4E-01	1.4E-01	1.0E-01	4.8E-02
3-Hydroxybutyric acid	3.2E-01	8.4E-01	8.7E-01	5.9E-01	1.4E+00	8.5E-01	1.0E+00	2.2E+00	4.4E-01	5.3E-01	5.3E-01	4.4E-01
2-Hydroxyisobutyric acid	5.4E-02	3.7E-02	4.3E-02	3.4E-02	4.6E-02	3.2E-02	2.5E-02	3.2E-02	1.8E-02	2.1E-02	9.5E-03	1.7E-02
2-Oxoisovaleric acid	4.4E-02	6.3E-02	1.1E-01	6.7E-02	5.6E-02	4.7E-02	6.8E-02	4.4E-02	4.5E-02	4.6E-02	2.9E-02	3.1E-02
Hexanoic acid	5.8E-02	5.5E-02	5.2E-02	5.3E-02	2.7E-02	4.0E-02	5.0E-02	4.9E-02	3.5E-02	2.6E-02	5.6E-02	5.7E-02
Succinic acid	8.7E-02	9.1E-02	7.1E-02	5.5E-02	1.7E-01	1.2E-01	8.2E-02	1.1E-01	4.3E-02	4.3E-02	8.2E-02	4.1E-02
2-Hydroxypentanoic acid	1.4E-01	1.2E-01	1.3E-01	2.0E-01	1.0E-01	1.3E-01	1.3E-01	9.0E-02	9.5E-02	9.0E-02	9.2E-02	8.6E-02
Isethionic acid	2.2E-02	1.6E-02	2.2E-02	2.1E-02	1.6E-02	1.8E-02	1.5E-02	2.6E-02	9.1E-03	1.0E-02	1.3E-02	1.2E-02
5-Oxoproline	3.7E-02	2.4E-02	2.1E-02	2.9E-02	2.8E-02	3.2E-02	3.0E-02	2.4E-02	3.2E-02	3.5E-02	4.2E-02	2.4E-02
4-Acetylbutyric acid	2.0E-02	2.4E-02	2.3E-02	2.4E-02	1.1E-02	1.7E-02	2.1E-02	2.4E-02	1.8E-02	9.6E-03	2.8E-02	3.0E-02
3-Methyl-2-oxovaleric acid	8.0E-02	2.2E-01	3.9E-01	3.1E-01	1.6E-01	1.3E-01	1.5E-01	6.5E-02	9.6E-02	1.1E-01	6.6E-02	5.5E-02
Heptanoic acid	2.9E-02	3.6E-02	3.2E-02	3.3E-02	1.4E-02	2.3E-02	2.5E-02	2.7E-02	1.8E-02	1.7E-02	3.2E-02	3.0E-02
Malic acid	1.7E-01	4.1E-01	5.2E-01	3.2E-01	3.6E-01	3.8E-01	3.8E-01	2.6E-01	1.6E-01	2.5E-01	1.9E-01	9.0E-02
o-Hydroxybenzoic acid	N.D.	3.0E-02	3.4E-02	N.D.	1.6E-02	4.1E-02	5.7E-02	N.D.	2.6E-02	1.6E-02	2.7E-02	1.6E-02
Ethanolamine phosphate	1.2E-02	1.1E-02	1.3E-02	1.2E-02	2.1E-02	1.3E-02	1.1E-02	1.9E-02	1.0E-02	1.5E-02	1.3E-02	9.6E-03
2-Oxoglutaric acid	1.2E-01	1.5E-01	2.4E-01	1.5E-01	1.3E-01	1.6E-01	2.0E-01	9.9E-02	7.3E-02	5.5E-02	6.3E-02	2.8E-02
Pelargonic acid	4.9E-02	4.6E-02	4.4E-02	5.0E-02	2.8E-02	4.7E-02	3.9E-02	4.2E-02	3.0E-02	2.1E-02	7.0E-02	3.5E-02
Uric acid	5.3E-02	6.1E-02	1.0E-01	6.4E-02	1.0E-01	7.1E-02	5.8E-02	5.5E-02	4.7E-02	4.5E-02	6.1E-02	3.2E-02
Glycerol-3-phosphate	3.0E-02	2.9E-02	2.2E-02	2.8E-02	3.0E-02	2.8E-02	2.0E-02	2.0E-02	1.9E-02	3.3E-02	2.8E-02	1.8E-02
Decanoic acid	2.4E-02	2.4E-02	2.4E-02	2.1E-02	2.5E-02	3.1E-02	2.2E-02	2.5E-02	2.1E-02	1.4E-02	3.5E-02	1.9E-02
cis-Aconitic acid	1.0E-01	1.4E-01	1.3E-01	1.1E-01	9.1E-02	1.0E-01	1.1E-01	1.2E-01	1.1E-01	9.3E-02	1.0E-01	8.6E-02
Hippuric acid	2.6E-02	1.6E-02	3.4E-02	1.3E-02	3.5E-02	2.6E-02	3.9E-02	2.9E-02	1.4E-02	2.1E-02	3.5E-02	3.6E-02
Citric acid	1.2E+00	1.8E+00	2.1E+00	1.4E+00	1.4E+00	1.4E+00	1.6E+00	1.5E+00	1.5E+00	1.3E+00	1.4E+00	1.0E+00
Isocitric acid	4.0E-02	9.4E-02	7.2E-02	7.3E-02	5.5E-02	6.0E-02	6.8E-02	8.2E-02	5.3E-02	6.7E-02	1.0E-01	6.0E-02
Glucuronic acid ; Galacturonic acid	1.7E-02	1.6E-02	1.7E-02	1.6E-02	1.4E-02	1.6E-02	1.3E-02	2.0E-02	1.3E-02	1.5E-02	1.6E-02	1.2E-02
Gluconic acid	5.8E-02	5.5E-02	6.1E-02	5.3E-02	7.5E-02	7.4E-02	5.5E-02	6.7E-02	4.8E-02	4.2E-02	4.3E-02	3.8E-02
S-Sulfocysteine	8.3E-03	1.5E-02	2.8E-02	2.7E-02	5.6E-03	6.8E-03	1.3E-02	8.8E-03	1.8E-02	1.1E-02	3.8E-02	1.6E-02
5-Methoxyindoleacetic acid	9.2E-03	2.4E-02	3.6E-02	1.4E-02	2.7E-02	2.3E-02	2.2E-02	1.3E-02	4.4E-03	9.8E-03	7.2E-03	4.6E-03
Phosphocreatine	1.7E-02	1.8E-02	1.5E-02	1.5E-02	1.5E-02	1.4E-02	1.1E-02	1.4E-02	1.3E-02	1.5E-02	1.1E-02	1.2E-02
3-Indoxylsulfuric acid	4.9E-02	1.0E-01	1.4E-01	9.1E-02	9.8E-02	9.1E-02	9.7E-02	7.5E-02	3.2E-02	6.1E-02	4.8E-02	3.6E-02
AMP	5.4E-03	2.0E-02	3.7E-03	9.8E-03	2.0E-02	1.1E-02	1.9E-02	2.1E-02	2.7E-03	4.8E-03	2.1E-02	3.8E-03
ADP	1.2E-03	2.0E-02	2.1E-03	3.8E-03	1.3E-02	6.2E-03	2.7E-02	6.9E-03	3.2E-03	1.6E-03	6.4E-03	1.4E-03
ATP	1.3E-03	3.5E-02	4.3E-03	6.2E-03	1.6E-02	8.9E-03	4.4E-02	5.1E-03	7.6E-03	2.1E-03	7.9E-03	1.9E-03
Taurocholic acid	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	2.9E-02	N.D.	N.D.	N.D.	N.D.	N.D.
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name
Glyoxylic acid
Propionic acid
Pyruvic acid
Butyric acid
Lactic acid
3-Methylbutanoic acid
2-Hydroxybutyric acid
3-Hydroxybutyric acid
2-Hydroxyisobutyric acid
2-Oxoisovaleric acid
Hexanoic acid
Succinic acid
2-Hydroxypentanoic acid
Isethionic acid
5-Oxoproline
4-Acetylbutyric acid
3-Methyl-2-oxovaleric acid
Heptanoic acid
Malic acid
o-Hydroxybenzoic acid
Ethanolamine phosphate
2-Oxoglutaric acid
Pelargonic acid
Uric acid
Glycerol-3-phosphate
Decanoic acid
cis-Aconitic acid
Hippuric acid
Citric acid
Isocitric acid
Glucuronic acid ; Galacturonic acid
Gluconic acid
S-Sulfocysteine
5-Methoxyindoleacetic acid
Phosphocreatine
3-Indoxylsulfuric acid
AMP
ADP
ATP
Taurocholic acid
METABOLITES_END
#END